Stamford Advocate – OxyContin maker Purdue Pharma accounted for about 3 percent of the prescription opioids produced in the U.S. between 2006 and 2012, according to newly released federal data — but the disclosure of the small market share is unlikely to tamp down the intense legal pressure from the state of Connecticut and hundreds of other plaintiffs.
Norwalk Hour – Connecticut’s newly unredacted lawsuit against Purdue Pharma excoriates the owners and former executives of the OxyContin maker for allegedly fueling the opioid crisis. It does not lambast public officials.
CT Post – Connecticut Attorney General William Tong released Tuesday an unredacted version of the state’s lawsuit against OxyContin maker Purdue Pharma, revealing emails from 2001 that he said showed company co-owner and former CEO and President Richard Sackler’s “shocking and offensive” disregard for victims of the opioid crisis — an assertion contested by Sackler’s attorney.
CT Post – Connecticut’s expanded lawsuit against Purdue Pharma and its owners positions the state to more aggressively pursue its claims, but does not assure a full redress of its allegations of deceptive marketing and fraudulent finances against the much-maligned OxyContin maker.
NPR – Share prices for the British drugmaker Indivior plunged today on the London Stock Exchange. The drop came on news that the U.S. Justice Department indicted the company on fraud and conspiracy charges.
Westport News – Six of the state’s 10 largest cities, and hundreds of others across the country, have sued OxyContin maker Purdue Pharma. So has Connecticut’s attorney general and more than 30 of his counterparts.
The Guardian – Drug company executives appearing in court in Boston this week have been accused of running “a criminal enterprise” and putting greed before patient safety as they pushed prescription narcotics during the opioids crisis, blighting the health of America.
Daily Heralds – Purdue Pharma, the controversial maker of OxyContin, and eyecare-pharmaceutical firm Ocular Therapeutix has announced a research partnership aiming to develop non-opioid pain treatments.